Massimo Levrero
Overview
Explore the profile of Massimo Levrero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
5541
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Begre L, Boyd A, Plissonnier M, Testoni B, Salazar-Vizcaya L, Suter-Riniker F, et al.
J Infect Dis
. 2024 Apr;
230(4):e954-e963.
PMID: 38626170
Background: We evaluated long-term trajectories of circulating hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg) in persons with and without hepatitis B surface antigen (HBsAg) loss during...
12.
Salerno D, Peruzzi G, Pascucci G, Levrero M, Belloni L, Pediconi N
Gene
. 2024 Mar;
913:148387.
PMID: 38499211
Background: Epigenetic mechanisms, including DNA methylation, histone modifications, and chromatin remodeling, are highly involved in the regulation of hepatocyte viability, proliferation, and plasticity. We have previously demonstrated that repression of...
13.
Pulito C, Mori F, Sacconi A, Goeman F, Ferraiuolo M, Pasanisi P, et al.
Cell Discov
. 2024 Mar;
10(1):29.
PMID: 38480687
No abstract available.
14.
Narmada B, Khakpoor A, Shirgaonkar N, Narayanan S, Aw P, Singh M, et al.
J Hepatol
. 2024 Feb;
81(1):42-61.
PMID: 38423478
Background & Aims: Hepatitis B surface antigen (HBsAg) loss or functional cure (FC) is considered the optimal therapeutic outcome for patients with chronic hepatitis B (CHB). However, the immune-pathological biomarkers...
15.
Chouik Y, Di Filippo M, Radenne S, Dumortier J, Moulin P, Levrero M
Liver Int
. 2024 Feb;
44(6):1474-1477.
PMID: 38421084
No abstract available.
16.
Li Z, Caron de Fromentel C, Kim W, Wang W, Sun J, Yan B, et al.
Cell Death Dis
. 2023 Nov;
14(11):786.
PMID: 38036507
Reduced expression of the RNA helicase DDX5 associated with increased hepatocellular carcinoma (HCC) tumor grade and poor patient survival following treatment with sorafenib. While immunotherapy is the first-line treatment for...
17.
Testoni B, Scholtes C, Plissonnier M, Paturel A, Berby F, Facchetti F, et al.
Gut
. 2023 Oct;
73(4):659-667.
PMID: 37879886
Objective: A convenient, reproducible biomarker of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) transcriptional activity is lacking. We measured circulating HBV RNA (cirB-RNA) in untreated and nucleos(t)ide analogues...
18.
Begre L, Boyd A, Salazar-Vizcaya L, Suter-Riniker F, Beguelin C, Rockstroh J, et al.
HIV Med
. 2023 Oct;
25(2):291-298.
PMID: 37816492
Objectives: Improving the understanding of the patterns of quantitative hepatitis B surface antigen (qHBsAg) trajectories associated with HBsAg loss is important in light of novel anti-hepatitis B virus agents being...
19.
Testoni B, Roca Suarez A, Battisti A, Plissonnier M, Heil M, Fontanges T, et al.
JHEP Rep
. 2023 Sep;
5(10):100841.
PMID: 37675272
Background & Aims: Finite duration of treatment associated with HBsAg loss is the current goal for improved therapeutic approaches against chronic HBV infection, as it indicates elimination or durable inactivation...
20.
Chouik Y, Lebosse F, Plissonnier M, Lega J, Pradat P, Antonini T, et al.
iScience
. 2023 Aug;
26(8):107427.
PMID: 37575179
Bacterial infections are the most frequent precipitating event in patients with acute decompensation of cirrhosis (AD) and are associated with high mortality. Early diagnosis is challenging due to cirrhosis-related systemic...